adamantane has been researched along with Kidney Diseases in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Helmy, MM; Mouneir, SM | 1 |
| Beytur, A; Cakir, M; Erden, Y; Sandal, S; Taslıdere, A; Tekin, C; Tekin, S | 1 |
| Cheng, F; Guo, X; He, J; Yuan, G; Zhang, J | 1 |
| Helal, MG; Said, E; Zaki, MMAF | 1 |
| Hirota, D; Kajitani, N; Kodera, R; Makino, H; Miyamoto, S; Oda, K; Ono, T; Shikata, K; Takatsuka, T; Usui, HK | 1 |
| Kitayama, T; Kunori, S; Myojo, K; Sakai, M; Uchii, M | 1 |
| Deng, J; Dong, H; Gu, S; Mu, Y; Shi, L | 1 |
| Foley, JE; Kothny, W; Lukashevich, V; Rendell, MS; Schweizer, A | 1 |
| Ateyya, H | 1 |
| Boulton, DW; Pfister, M; Zhang, L | 1 |
| Ali, S; Fonseca, V | 1 |
| Hammock, BD; Imig, JD; Kim, IH; Newman, JW; Olearczyk, JJ; Pollock, DM; Watanabe, T; Zaharis, CZ; Zhao, X | 1 |
| Burghardt, RC; Chen, G; Hammock, BD; Morisseau, C; Parrish, AR; Watanabe, T | 1 |
1 review(s) available for adamantane and Kidney Diseases
| Article | Year |
|---|---|
Saxagliptin overview: special focus on safety and adverse effects.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Dosage Calculations; Drug Interactions; Humans; Kidney Diseases; Liver Diseases; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
1 trial(s) available for adamantane and Kidney Diseases
| Article | Year |
|---|---|
Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
Topics: Adamantane; Aged; Blood Glucose; Brazil; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; United States; Vildagliptin | 2015 |
11 other study(ies) available for adamantane and Kidney Diseases
| Article | Year |
|---|---|
Reno-protective effect of linagliptin against gentamycin nephrotoxicity in rats.
Topics: Adamantane; Animals; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gentamicins; Kidney; Kidney Diseases; Linagliptin; Male; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate | 2019 |
Protective effect of saxagliptin against renal ischaemia reperfusion injury in rats.
Topics: Adamantane; Animals; Dipeptides; Kidney; Kidney Diseases; Rats; Reperfusion Injury | 2022 |
Mast Cell and M1 Macrophage Infiltration and Local Pro-Inflammatory Factors Were Attenuated with Incretin-Based Therapies in Obesity-Related Glomerulopathy.
Topics: Adamantane; Albuminuria; Animals; Creatinine; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucose Tolerance Test; Incretins; Inflammation; Interleukin-6; Kidney Diseases; Kidney Glomerulus; Liraglutide; Macrophages; Male; Mast Cells; Nitriles; Obesity; Pyrrolidines; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Vildagliptin | 2017 |
Nephroprotective effect of saxagliptin against gentamicin-induced nephrotoxicity, emphasis on anti-oxidant, anti-inflammatory and anti-apoptic effects.
Topics: Adamantane; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Gentamicins; Kidney Diseases; Kidney Function Tests; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2018 |
Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glucagon-Like Peptide 1; Kidney Diseases; Kidney Glomerulus; Male; Nitriles; Protective Agents; Pyrrolidines; Rats; Rats, Sprague-Dawley | 2014 |
Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
Topics: Adamantane; Albuminuria; Animals; Blood Glucose; Blood Pressure; Cytoprotection; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension; Kidney Diseases; Kidney Glomerulus; Male; Rats, Inbred Dahl; Sitagliptin Phosphate | 2015 |
Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
Topics: Adamantane; Body Mass Index; Cardiovascular Diseases; China; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Female; Hospital Costs; Humans; Hypoglycemia; Hypoglycemic Agents; Insurance Claim Review; Kidney Diseases; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2015 |
Amelioration of cyclosporine induced nephrotoxicity by dipeptidyl peptidase inhibitor vildagliptin.
Topics: Adamantane; Animals; bcl-2-Associated X Protein; Blood Urea Nitrogen; Creatinine; Cyclosporine; Dipeptidyl-Peptidase IV Inhibitors; Glutathione; Immunosuppressive Agents; Kidney; Kidney Diseases; L-Lactate Dehydrogenase; Lipid Peroxidation; Male; Nitriles; Protective Agents; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Rats, Wistar; Serum Albumin; Superoxide Dismutase; Vildagliptin | 2015 |
A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.
Topics: Adamantane; Chronic Disease; Computer Simulation; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Kidney Diseases; Models, Biological; Renal Dialysis | 2012 |
An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.
Topics: Adamantane; Albuminuria; Angiotensins; Animals; Blood Pressure; Cell Count; Epoxide Hydrolases; Hypertension; Kidney; Kidney Diseases; Lauric Acids; Macrophages; Male; Rats; Rats, Sprague-Dawley; Sodium Chloride | 2005 |
Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase.
Topics: Adamantane; Animals; Antineoplastic Agents; Blood Urea Nitrogen; Chromatography, High Pressure Liquid; Cisplatin; Drug Antagonism; Enzyme Inhibitors; Epoxide Hydrolases; Injections, Subcutaneous; Kidney; Kidney Diseases; Lauric Acids; Male; Mice; Mice, Inbred C3H; Microsomes, Liver; Rats; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2009 |